ahlam1399
07-24-2015, 03:33 PM
Biogen profit rises 30 pct on higher Tecfidera sales
July 24 (Reuters) - Biogen Inc reported a 30 percent rise in quarterly profit, driven by strong sales of its top-selling oral multiple sclerosis drug, Tecfidera.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4866e0f4/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=R351WEeIasQ:iAYv3x2NxRU:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=R351WEeIasQ:iAYv3x2NxRU:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=R351WEeIasQ:iAYv3x2NxRU:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=R351WEeIasQ:iAYv3x2NxRU:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=R351WEeIasQ:iAYv3x2NxRU:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/R351WEeIasQ
July 24 (Reuters) - Biogen Inc reported a 30 percent rise in quarterly profit, driven by strong sales of its top-selling oral multiple sclerosis drug, Tecfidera.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4866e0f4/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=R351WEeIasQ:iAYv3x2NxRU:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=R351WEeIasQ:iAYv3x2NxRU:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=R351WEeIasQ:iAYv3x2NxRU:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=R351WEeIasQ:iAYv3x2NxRU:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=R351WEeIasQ:iAYv3x2NxRU:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/R351WEeIasQ